Edition:
United Kingdom

BioArctic AB (BIOAb.ST)

BIOAb.ST on Stockholm Stock Exchange

99.90SEK
15 Feb 2019
Change (% chg)

2.15kr (+2.20%)
Prev Close
97.75kr
Open
97.65kr
Day's High
100.00kr
Day's Low
96.10kr
Volume
313,949
Avg. Vol
226,321
52-wk High
172.00kr
52-wk Low
20.40kr

Latest Key Developments (Source: Significant Developments)

Bioarctic Q4 EBIT Up At SEK 430.3 Million
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - BioArctic AB ::Q4 NET SALES SEK 515.3 MILLION VERSUS SEK 51.0 MILLION YEAR AGO.Q4 EBIT SEK 430.3 MILLION VERSUS SEK 14.7 MILLION YEAR AGO.BOARD OF DIRECTORS PROPOSES A DIVIDEND OF SEK 1.50 PER SHARE FOR FISCAL YEAR 2018.  Full Article

Bioarctic Q3 EBIT Rises To SEK 33.1 Million
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - BioArctic AB ::Q3 NET REVENUE SEK 94.0 MILLION VERSUS SEK 31.5 MILLION YEAR AGO.Q3 EBIT SEK 33.1 MILLION VERSUS SEK 0.6 MILLION YEAR AGO.  Full Article

BioArctic: Additional Ban2401 Phase 2B Study Results In Early Alzheimer's Disease
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - AB ::BIOARCTIC ANNOUNCES ADDITIONAL BAN2401 PHASE 2B STUDY RESULTS IN EARLY ALZHEIMER'S DISEASE PRESENTED BY EISAI AT THE 2018 CTAD CONFERENCE.STATISTICALLY SIGNIFICANT BENEFITS WERE OBSERVED ON KEY EFFICACY ENDPOINTS AT 18 MONTH ON SLOWING PROGRESSION IN ALZHEIMER'S DISEASE COMPOSITE SCORE (ADCOMS).STATISTICALLY SIGNIFICANT BENEFITS WERE OBSERVED ON REDUCTION OF AMYLOID ACCUMULATED IN BRAIN AS MEASURED BY USING AMYLOID-PET AT HIGHEST TREATMENT DOSE.PRE-SPECIFIED ANALYSES SHOW GOOD TOLERABILITY PROFILE OF BAN2401 WITH DOSE-DEPENDENT, CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT EFFECTS ON SEVERAL CLINICAL ENDPOINTS.CO'S PARTNER EISAI IS CURRENTLY DISCUSSING NEXT STEPS FOR BAN2401 WITH REGULATORY AUTHORITIES.  Full Article

BioArctic Receives European Patent Protection
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - BioArctic AB ::BIOARCTIC RECEIVES EUROPEAN PATENT PROTECTION FOR A MEDICAL DEVICE FOR TREATMENT OF PATIENTS WITH COMPLETE SPINAL CORD INJURY.PATENT, EP 2 787 900 B1, WILL ENTER INTO FORCE ON OCTOBER 24, 2018..  Full Article

Bioarctic Q2 Operating Profit Amounted To Sek 6.4 Million
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - BioArctic AB ::APRIL-JUNE NET REVENUES FOR PERIOD AMOUNTED TO SEK 52.3 MILLION (32.0).APRIL-JUNE OPERATING PROFIT AMOUNTED TO SEK 6.4 MILLION (2.5).  Full Article

BioArctic Receives Regulatory Approval In Finland For Clinical Study
Tuesday, 10 Jul 2018 

July 10 (Reuters) - BioArctic AB ::BIOARCTIC RECEIVES REGULATORY APPROVAL IN FINLAND FOR A CLINICAL STUDY IN PATIENTS WITH COMPLETE SPINAL CORD INJURY.APPROVAL MEANS THAT BIOARCTIC HAS RECEIVED APPROVALS IN ALL COUNTRIES PLANNED TO PARTICIPATE IN STUDY.  Full Article

Bioarctic Says Positive Topline Results Of Ban2401 Phase 2B At 18 Months In Early Alzheimer's Disease
Friday, 6 Jul 2018 

July 5 (Reuters) - BioArctic AB ::BIOARCTIC ANNOUNCES POSITIVE TOPLINE RESULTS OF BAN2401 PHASE 2B AT 18 MONTHS IN EARLY ALZHEIMER'S DISEASE.  Full Article

BioArctic Extends Research Collaboration With Uppsala University
Monday, 14 May 2018 

May 14 (Reuters) - BioArctic AB ::BIOARCTIC EXTENDS THE RESEARCH COLLABORATION WITH UPPSALA UNIVERSITY REGARDING NEW ANTIBODY TECHNOLOGY.EXTENDED RESEARCH COLLABORATION CONCERNS TECHNOLOGIES FOR INCREASED PASSAGE ACROSS BLOOD-BRAIN BARRIER.WILL CONTRIBUTE FINANCIAL SUPPORT FOR A THREE YEAR POST-DOC RESEARCH POSITION..  Full Article

BioArctic Q3 operating results swings to profit of SEK 0.6 mln​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - BIOARCTIC AB :‍NET SALES FOR JULY-SEPT AMOUNTED TO SEK 31.5 MILLION (1.2)​.‍JULY-SEPT OPERATING PROFIT AMOUNTED TO SEK 0.6 MILLION (-10.2)​.‍JULY-SEPT LOSS AMOUNTED TO SEK -0.1 MILLION (-7.8)​.  Full Article